Lassa Fever Clinical Trials

Find Lassa Fever Clinical Trials Near You

A Randomized, Placebo-controlled Trial, to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever, in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase

Status: Recruiting
Location: See location...
Intervention Type: Biological, Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Lassa fever is an acute viral disease belonging to the category of viral hemorrhagic fevers. It is endemic in West Africa. Outbreaks occur every year, and it is estimated that between 100 000 and 300 000 individuals are infected each year, with a fatality rate for symptomatic cases that ranges between 15 and 30%. There is no efficient treatment against the disease, as ribavirin, the only licensed therapy, is at best poorly efficient. MOPEVAC-Las is a live-attenuated vaccine candidate targeting Lassa virus. The objective of this phase 1 clinical trial is to evaluate the safety of the MOPEVAC-Las vaccine candidate on healthy volunteers. It will also evaluate the immunogenicity and optimal dose of the vaccine candidate. The main questions it aims to answer are: * What are the safety and tolerability of the MOPEVAC-Las vaccine candidate following two intramuscular injections in healthy volunteers ? * Are cell-mediated immunity and humoral immunity induced by the MOPEVAC-Las vaccine ? * What is the optimal dose of MOPEVAC-Las vaccine regarding safety, tolerability and immunogenicity ? Researchers will compare the MOPEVAC-Las vaccine candidate to a placebo (a look-alike substance that contains no drug).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: t
View:

• Males and females between the ages of 18 and 55 years (at the time of consent).

• Healthy participant, according to the investigator's clinical judgment, as established by medical history, vital signs, physical examination, and laboratory assessments.

• Participant with a body mass index (BMI) between 18,5 kg/m2 and 30.0 kg/m2.

• Provide written informed consent before initiation of any study procedures.

• A female participant is eligible for this study if she is not pregnant, given by a negative serum pregnancy test at screening and a negative urine pregnancy test at V1 (first injection), nor breastfeeding and if she meets any of the following criteria:

‣ Of non-childbearing potential (i.e., women who have had a hysterectomy or surgical tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).

⁃ Of childbearing potential but having sexual relations exclusively with female partners.

⁃ Of childbearing potential but has been and agrees to continue practicing highly effective contraception or abstinence (if this is the preferred and usual lifestyle of the participant) from 30 days prior to vaccination up to 6 months after the last injection (D242).

• Highly effective methods of contraception include 1 or more of the following:

⁃ Male partner who is sterile prior to the female participants entry into the study and is the sole sexual partner for the female participant

⁃ Compliant hormonal therapy (oral, intravaginal, transdermal, implantable or injectable)

⁃ An intrauterine hormone-releasing system (IUS)

⁃ An intrauterine device (IUD) with a documented failure rate of \< 1%

• A female participant is eligible if she agrees to abstain from donating oocyte from the screening visit up to 6 months after the last injection (D242)

• A male participant is eligible if he agrees to:

‣ Use a condom (with/without spermicidal product) from the screening visit up to 6 months after the last injection (D242) except if the male participant is sterile; the unique female sexual partner is postmenopausal (defined as no menses for 12 months without an alternative medical cause), is permanently sterilized (e.g. hysterectomy or tubal ligation), or use a highly effective method of contraception; or if he has sexual relations exclusively with male partners

⁃ Not donate sperm from the screening visit up to 6 months after the last injection (D242)

⁃ Not plan to father a child from the screening visit up to 6 months after the last injection (D242)

• Negative HIV 1/2 antibody/antigen test, Hepatitis B surface antigen (HBsAg), and Hepatitis C virus (HCV) antibody.

• Able to understand and comply with planned study procedures and willing to be available for all study-required procedures, visits and calls for the duration of the study.

⁃ Willing to abstain from donating whole blood or blood derivatives, tissue or organ all along the study.

⁃ Affiliated to a social security system (except state medical aid).

Locations
Other Locations
France
Centre d'Investigation Clinique en Vaccinologie Cochin-Pasteur
RECRUITING
Paris
Contact Information
Primary
Sandrine Fernandes Pellerin
sandrine.fernandespellerin@pasteur.fr
+33145688179
Backup
Maëlys Petit-Moreau
maelys.petit-moreau@pasteur.fr
+33176535439
Time Frame
Start Date: 2026-09-28
Estimated Completion Date: 2028-12
Participants
Target number of participants: 72
Treatments
Experimental: Low dose
Experimental: Intermediate dose
Experimental: High dose
Related Therapeutic Areas
Sponsors
Leads: Institut Pasteur

This content was sourced from clinicaltrials.gov